Therefore, drugs that selectively inhibit HIF-1α or upregulate HIF-2α in the CB, modulating the expression of NADPH oxidase 2 and Sod2 enzymes, could be potential targets for hypertension and OSA. Here, HIF1A is linked to hypertensive disorder.